Do you want to read an article? Please log in or register.
Eosinophil persistence in vivo and sustained viability ex vivo in response to respiratory challenge with fungal allergens
Related content
AsthmaRespiratory Tract Infection
Allergen immunotherapy for the treatment of respiratory allergies in the elderly
Curr Opin Allergy Clin Immunol.
Hur GY, Lee JH, Park HS
doi: 10.1097/
RECOMMENDED
Asthma
Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med.
Albers FC, Licskai C, Chanez P, Bratton DJ, Bradford ES, Yancey SW, Kwon N, Quirce S
doi: 10.1016/j.rmed.2019.105806.
Clinical Outcome of Eosinophilic Airway Inflammation in Chronic Airway Diseases Including Nonasthmatic Eosinophilic Bronchitis
Sci Rep.
Cho J, Choi SM, Lee J, Park YS, Lee SM, Yoo CG, Kim YW, Han SK, Lee CH
doi: 10.1038/
COMMENTED
ARDSAsthma
Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial
Lancet Respir Med.
Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, Laffey JG, O'Kane CM, McAuley DF, Irish Critical Care Trials Group
doi: 10.1016/
Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial
Lancet Respir Med.
Price DB, Buhl R, Chan A, Freeman D, Gardener E, Godley C, Gruffydd-Jones K, McGarvey L, Ohta K, Ryan D, Syk J, Tan NC, Tan T, Thomas M, Yang S, Konduru PR, Ngantcha M, d'Alcontres MS, Lapperre TS
doi: 10.1016/
RECOMMENDED
Asthma
Sub-optimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J.
Mukherjee M, Forero DF, Tran S, Boulay ME, Bertrand M, Bhalla A, Cherukat J, Al-Hayyan H, Ayoub A, Revill SD, Javkar T, Radford K, Kjarsgaard M, Huang C, Dvorkin-Gheva A, Ask K, Olivenstein R, Dendukuri N, Lemiere C, Boulet LP, Martin JG, Nair P
doi: 10.1183/13993003.00117-2020.
Asthma
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Respir Med.
Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M; BISE Study Investigators
doi: 10.1016/
COPD
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.
Respir Res.
Cazzola M, Calzetta L, Facciolo F, Rogliani P, Matera MG
doi: 10.1186/s12931-016-0500-y.
RECOMMENDED
AsthmaCOPD
Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Thorax
David B, Bafadhel M, Koenderman L, De Soyza A
doi: 10.1136/thoraxjnl-2020-215167